docetaxel anhydrous has been researched along with Minimal Disease, Residual in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 10 (28.57) | 29.6817 |
| 2010's | 19 (54.29) | 24.3611 |
| 2020's | 5 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Boniface, CT; Spellman, PT | 1 |
| Ambroggi, M; Bisagni, G; Bria, E; Campanini, N; Carbognin, L; Casarini, C; Cretella, E; Fiorio, E; Frassoldati, A; Gianni, L; Gori, S; Maglietta, G; Missale, G; Montemurro, F; Mura, A; Musolino, A; Pellegrino, B; Serra, O; Silini, EM; Todeschini, R; Tognetto, M; Tommasi, C; Zamagni, C; Zambelli, A | 1 |
| Habuchi, T; Hiroshima, Y; Inoue, T; Kanda, S; Koizumi, A; Matsuda, Y; Mingguo, H; Nanjo, H; Nara, T; Narita, S; Numakura, K; Saito, M; Sato, H; Satoh, S; Tsuchiya, N | 1 |
| Bienkowska, J; Bonato, V; Ching, KA; Cho, SY; Choi, YL; Deng, S; Ding, Y; Fernandez, D; Hwang, S; Kan, Z; Kang, ES; Kim, J; Kim, JY; Kim, SW; Kim, YJ; Lal, S; Lee, JE; Lee, SH; Lee, SK; Nam, JY; Nam, SJ; Park, S; Park, WY; Park, YH; Powell, E; Ram, S; Rejto, PA; Shin, H; Wang, S; Wen, J; Yu, JH | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, PC; Egle, D; Exner, R; Filipits, M; Fitzal, F; Frantal, S; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Muy-Kheng, TM; Petru, E; Petzer, AL; Pfeiler, G; Pichler, A; Rudas, M; Sevelda, P; Singer, CF; Stoeger, H; Tinchon, C; Wette, V | 1 |
| Ahlgren, GM; Angelsen, A; Borre, M; Flodgren, P; Iversen, JR; Jonsson, E; Kellokumpu-Lehtinen, P; Sengelov, L; Sverrisdottir, A; Tammela, TLJ | 1 |
| Bondiau, PY; Chamorey, E; Cohen, C; Doyen, J; Gal, J; Gérard, A; Guerder, C; Ianessi, A; Leysalle, A; Naghavi, AO; Otto, J; Padovani, B; Poudenx, M; Schiappa, R | 1 |
| Kazuno, A; Koyanagi, K; Ninomiya, Y; Oguma, J; Ozawa, S; Yamamoto, M; Yatabe, K | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Fujita, K; Hatano, K; Kaneda, Y; Murakami, K; Nagahara, A; Nakai, Y; Nakayama, M; Nimura, K; Nonomura, N; Tsuchiya, M; Uemura, M; Yamaguchi, S | 1 |
| Battafarano, RJ; Burrows, WM; Edelman, MJ; Hanlon, AL; Horiba, MN; Kim, GJ; Koshy, M; Suntharalingam, M | 1 |
| Duan, L; Fang, L; Long, X; Qu, H | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Kang, Y; Li, J; Ma, Y; Ren, W; Zang, L; Zhang, S | 1 |
| Beesley, J; Brown, R; Byth, K; Chenevix-Trench, G; DeFazio, A; Fereday, S; Harnett, PR; Johnatty, SE; Marsh, S; McLeod, H; Paul, J; Spurdle, AB; Webb, PM | 1 |
| Ah-See, ML; Beresford, MJ; Collins, DJ; d'Arcy, JA; Li, SP; Makris, A; Padhani, AR; Stirling, JJ; Taylor, NJ | 1 |
| Collie-Duguid, ES; Heys, SD; Miller, ID; Smyth, E; Stewart, KN; Sweeney, K | 1 |
| Danno, K; Imaoka, S; Inatome, J; Kagara, N; Kagawa, K; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Watanabe, A | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Anderson, J; Barham, T; Chan, A; Hastrich, DJ; Ingram, D; Joseph, D; Latham, B; Redfern, A; Thomson, J; VAN DER Schaaf, A; Willsher, PC | 1 |
| Fujii, Y; Kihara, K; Komai, Y; Noguchi, N; Waseda, Y; Yano, A | 1 |
| Caldés, T; de la Hoya, M; Díaz-Rubio, E; Fuentes-Ferrer, M; Furió, V; García-Sáenz, JA; López Garcia-Asenjo, JA; Martín, M; Moreno, A; Román, JM; Romero, A | 1 |
| Jonkers, J; Rottenberg, S | 1 |
| Borgen, E; Kersten, C; Mjaaland, I; Naume, B; Nesland, JM; Risberg, T; Schirmer, C; Synnestvedt, M; Vindi, L; Weyde, K; Wiedswang, G; Wist, E | 1 |
| Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E | 1 |
| Arbion, F; Body, G; Brunereau, L; Chapiron, C; Denis, F; Desbiez-Bourcier, AV | 1 |
| Erban, J; Gradishar, WJ; Jahanzeb, M; Limentani, SA; Olsen, SR; Swain, SM; Tsai, KT; Wedam, SB | 1 |
| Bartz, B; Carson, PL; Fowlkes, JB; Gordon, SP; Johnson, TD; LeCarpentier, GL; Pai, D; Roubidoux, MA; Schott, AF | 1 |
| Baker, LH; Griffith, KA; Hayes, DF; Helvie, MA; Hunt, KA; Kleer, CG; Murray, S; Newman, LA; Paramagul, C; Pierce, LJ; Roubidoux, MA; Schott, AF | 1 |
| Douek, M; Tobias, J | 1 |
| Baghi, M; Bisdas, S; Gstoettner, W; Hambek, M; Knecht, R; Mack, MG; Muerthel, R; Vogl, T; Wagenblast, J | 1 |
| Chao, KS | 1 |
| Ahn, JS; Choe, YH; Choi, N; Choi, YL; Han, BK; Im, YH; Kim, HJ; Kim, JH; Ko, YH; Lee, J; Nam, SJ; Park, YS; Yang, JH | 1 |
| Gnant, M; Jakesz, R; Locker, GJ; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G | 1 |
1 review(s) available for docetaxel anhydrous and Minimal Disease, Residual
| Article | Year |
|---|---|
Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.
Topics: Biomarkers, Tumor; Circulating Tumor DNA; Docetaxel; Humans; Liquid Biopsy; Mutation; Neoplasm, Residual | 2022 |
11 trial(s) available for docetaxel anhydrous and Minimal Disease, Residual
| Article | Year |
|---|---|
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Tumor Burden | 2021 |
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Postoperative Period; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Factors; Survival Rate; Watchful Waiting | 2018 |
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiosurgery; Taxoids; Treatment Outcome | 2018 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prospective Studies; Taxoids | 2004 |
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Image Processing, Computer-Assisted; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Ultrasonography, Doppler, Color; Ultrasonography, Mammary | 2005 |
How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Taxoids | 2005 |
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids | 2000 |
23 other study(ies) available for docetaxel anhydrous and Minimal Disease, Residual
| Article | Year |
|---|---|
Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Docetaxel; Gene Knockdown Techniques; Humans; Male; Neoadjuvant Therapy; Neoplasm, Residual; Prostatic Neoplasms; Survival Analysis; Tissue Array Analysis; Transcription Factors; Up-Regulation; YAP-Signaling Proteins | 2020 |
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Topics: Anthracyclines; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Ductal, Breast; CD8-Positive T-Lymphocytes; Cell Cycle Proteins; Cyclophosphamide; Disease-Free Survival; Docetaxel; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Interferon Regulatory Factors; Longitudinal Studies; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neoplasm, Residual; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Tumor Microenvironment | 2020 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cyclams; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Male; MAP Kinase Signaling System; Mice, Nude; Mice, SCID; Neoplasm, Residual; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, CXCR4; Signal Transduction; Taxoids | 2013 |
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Proportional Hazards Models; Retrospective Studies; Taxoids | 2016 |
[Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cadherins; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; RNA, Messenger; Taxoids; Vimentin | 2014 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Elasticity Imaging Techniques; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Ultrasonography, Mammary | 2016 |
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2008 |
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; ROC Curve; Statistics, Nonparametric; Taxoids | 2010 |
SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Docetaxel; Female; HSP70 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm, Residual; Prognosis; Randomized Controlled Trials as Topic; Serpins; Taxoids; Treatment Outcome | 2012 |
Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Radiosurgery; Taxoids | 2014 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Preoperative Care; Quality of Life; Taxoids; Treatment Outcome | 2012 |
Pathological complete response and two-year disease-free survival in a primary gastric choriocarcinoma patient with advanced liver metastases treated with germ cell tumor-based chemotherapy: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Choriocarcinoma, Non-gestational; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Disease-Free Survival; Docetaxel; Etoposide; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm, Residual; Stomach Neoplasms; Survival Analysis; Taxoids | 2012 |
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Proportional Hazards Models; Taxoids; Treatment Outcome; Tumor Burden | 2013 |
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Dual-Specificity Phosphatases; Extracellular Signal-Regulated MAP Kinases; Female; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Phosphatases; Mitogen-Activated Protein Kinases; Neoplasm Recurrence, Local; Neoplasm, Residual; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA Interference; Taxoids | 2012 |
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoplasm, Residual; Taxoids; Treatment Outcome; Young Adult | 2012 |
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Hospitals, High-Volume; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diagnostic Imaging; Docetaxel; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Mammography; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Palpation; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Ultrasonography, Mammary | 2005 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Endoscopy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prognosis; Remission Induction; Taxoids | 2007 |
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2007 |
Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prognosis; Reproducibility of Results; Taxoids; Treatment Outcome | 2007 |